Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

ABSTRACT: Lung cancer is one of the malignant tumor diseases with high morbidity and high mortality in the world. Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer ...

Onco-Innovations’ licensed technology demonstrates promise to enhance chemotherapy effectiveness by overcoming cancer cell resistance: Vancouver, BC Saturday, February 1, 2025, ...

Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Specifically, the novel Trop-2-directed antibody and topoisomerase inhibitor conjugate is indicated for those who have ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...